Sebastiaan Camiel Goulooze
Overview
Explore the profile of Sebastiaan Camiel Goulooze including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
23
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Goulooze S, Snelder N
CPT Pharmacometrics Syst Pharmacol
. 2024 Jul;
13(8):1285-1288.
PMID: 39010750
No abstract available.
2.
Eissing T, Goulooze S, van den Berg P, van Noort M, Ruppert M, Snelder N, et al.
Diabetes Obes Metab
. 2023 Dec;
26(3):924-936.
PMID: 38037539
Aims: To perform dose-exposure-response analyses to determine the effects of finerenone doses. Materials And Methods: Two randomized, double-blind, placebo-controlled phase 3 trials enrolling 13 026 randomized participants with type 2...
3.
Goulooze S, Heerspink H, van Noort M, Snelder N, Brinker M, Lippert J, et al.
Clin Pharmacokinet
. 2022 May;
61(7):1013-1025.
PMID: 35508594
Background And Objective: Finerenone reduces the risk of kidney failure in patients with chronic kidney disease and type 2 diabetes. Changes in the urine albumin-to-creatinine ratio (UACR) and estimated glomerular...
4.
Goulooze S, Snelder N, Seelmann A, Horvat-Broecker A, Brinker M, Joseph A, et al.
Clin Pharmacokinet
. 2021 Nov;
61(3):451-462.
PMID: 34786651
Background: Finerenone is a nonsteroidal selective mineralocorticoid receptor antagonist (MRA) that demonstrated efficacy in delaying the progression of chronic kidney disease (CKD) and reducing cardiovascular events in patients with CKD...